<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334906</url>
  </required_header>
  <id_info>
    <org_study_id>MEM-MD-15</org_study_id>
    <nct_id>NCT00334906</nct_id>
  </id_info>
  <brief_title>Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)</brief_title>
  <official_title>An Open-Label Exploratory Study With Memantine: Assessment of Selected Measures of Volumetric MRI and Cognition in Patients With Moderate Dementia of the Alzheimer's Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the progression of disease using volumetric MRI
      techniques and cognitive outcome measures in patients with moderate dementia of the
      Alzheimer's type treated with open-label memantine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Total brain atrophy on MRI</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other measures of brain atrophy on MRI, change from baseline in selected cognitive measures assessing multiple cognitive domains including memory, attention, motor-speed, auditory comprehension, and verbal fluency</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment>75</enrollment>
  <condition>Alzheimer's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>memantine HCl</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory male or female patients at least 50 years of age (females at least 2 years
             postmenopausal)

          -  A diagnosis of probable AD [according to the National Institute of Neurological and
             Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders
             Associations (NINCDS-ADRDA) criteria] of moderate severity [Mini-Mental State
             Examination score between 15 and 20, inclusive]

          -  On a stable dose of Food and Drug Administration (FDA)-approved acetylcholinesterase
             inhibitor

        Exclusion Criteria:

          -  Current Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV)
             Axis I disorder other than AD

          -  Previous imaging results not consistent with the diagnosis of AD

          -  Modified Hachinski Ischemia Score greater than 4

          -  Evidence of other neurologic disorders

          -  Inability to participate in MRI testing

          -  No clinically significant systemic disease

          -  A known or suspected history of alcohol or drug abuse in the past 10 years

          -  Taking excluded medication

          -  Previous treatment with commercial memantine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Forest Laboratories</name>
      <address>
        <city>Jersey City</city>
        <state>New Jersey</state>
        <zip>07311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2006</study_first_submitted>
  <study_first_submitted_qc>June 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2006</study_first_posted>
  <last_update_submitted>January 3, 2008</last_update_submitted>
  <last_update_submitted_qc>January 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2008</last_update_posted>
  <keyword>memantine</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>MRI</keyword>
  <keyword>moderate Alzheimer's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

